Effects of Apatinib combined with FOLFOX chemotherapy in treatment of patients with advanced gastric cancer
Objective:To observe effects of Apatinib combined with FOLFOX chemotherapy in treatment of patients with advanced gastric cancer.Methods:A prospective study was conducted on 80 patients with advanced gastric cancer admitted to the hospital from June 2021 to June 2023.According to the random number table method,they were divided into observation group and control group,40 cases in each group.The control group was treated with FOLFOX chemotherapy,while the observation group was treated with Apatinib on the basis of that of the control group.Both groups were treated for 2 cycles.The clinical efficacy,the tumor markers[carbohydrate antigen 19-9(CA19-9),carcinoembryonic antigen(CEA),carbohydrate antigen 72-4(CA72-4),carbohydrate antigen 125(CA125)]levels,the quality of life[European organization for research and treatment of cancer quality of life core questionnaire scale(EORTC QLQ-C30)]scores before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The disease control rate(DCR)of the observation group was 92.50%(37/40),which was higher than 72.50%(29/40)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of CEA,CA19-9,CA72-4 and CA125 in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the scores of functional scale and total health status scale of EORTC QLQ-C30 in the observation group were higher than those in the control group,the scores of symptom scale were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions such as oral mucositis,bone marrow suppression,liver function damage,nausea and vomiting between the two groups(P>0.05).Conclusions:Apatinib combined with FOLFOX chemotherapy in the treatment of the patients with advanced gastric cancer can improve the DCR,reduce the levels of tumor markers,and improve the quality of life.Moreover,it is superior to simple FOLFOX chemotherapy.
AdvanceGastric cancerApatinibChemotherapyTumor markerQuality of lifeFOLFOX chemotherapy
万方数据
维普
